BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa
09 June 2022 - 10:31PM
MAINZ, Germany, June 9, 2022 (GLOBE
NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”)
will welcome its African partners for the first time on the African
continent and provide an update on the joint establishment of mRNA
manufacturing facilities and vaccine development plans. The event
will encompass the groundbreaking for BioNTech’s initial African
mRNA manufacturing facility in Kigali, Rwanda, where the first
BioNTainer modules are planned to be delivered by the end of
2022.
Following the invitation of H.E. President Paul
Kagame of Rwanda, several heads of States and Government are
expected to attend, alongside highest-level representatives from
the African Union, the European Union, and WHO. The event will take
place on June 23, 2022, at approx. 11.30 am CET / 05.30 am ET. A
limited number of accredited media representatives will be able to
join the event on-site. Interested journalists are invited to send
an e-mail with the subject line “BioNTainer in Africa”.
In February 2022, BioNTech introduced its
approach to establish scalable vaccine production by developing and
delivering turnkey mRNA manufacturing facilities based on a
container solution named “BioNTainer”. BioNTech also expects to
ship BioNTainers to Senegal and potentially South Africa in close
coordination with the respective country and the African Union.
About BioNTech
Biopharmaceutical New Technologies is a next generation
immunotherapy company pioneering novel therapies for cancer and
other serious diseases. The Company exploits a wide array of
computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor T cells, bi-specific checkpoint immuno-modulators,
targeted cancer antibodies and small molecules. Based on its deep
expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing
multiple mRNA vaccine candidates for a range of infectious diseases
alongside its diverse oncology pipeline. BioNTech has established a
broad set of relationships with multiple global pharmaceutical
collaborators, including Genmab, Sanofi, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For
more information, please visit www.BioNTech.de.
CONTACTS
Investor Relations Sylke Maas, Ph.D. VP
Investor Relations & Strategy Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
Media Relations Jasmina Alatovic VP Corporate
Communications Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385
E-mail: Media@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2023 to Mar 2024